Browsing by Author "Harrison, Michael R"
Now showing items 1-6 of 6
-
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
(Cancer, 2020-08-05)BACKGROUND:Inhibition of the programmed cell death protein 1 (PD-1) pathway has demonstrated clinical benefit in metastatic urothelial cancer (mUC); however, response rates of 15% to 26% highlight the need for more effective ... -
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC).
(Cancer, 2021-07)<h4>Background</h4>Systemic therapy (ST) can be deferred in patients who have metastatic renal cell carcinoma (mRCC) and slow-growing metastases. Currently, this subset of patients managed with active surveillance (AS) is ... -
Development of a Novel c-MET-Based CTC Detection Platform.
(Mol Cancer Res, 2016-06)UNLABELLED: Amplification of the MET oncogene is associated with poor prognosis, metastatic dissemination, and drug resistance in many malignancies. We developed a method to capture and characterize circulating tumor cells ... -
LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.
(Journal for immunotherapy of cancer, 2021-03)<h4>Background</h4>Low-density lipoprotein receptor-related protein 1b (encoded by LRP1B) is a putative tumor suppressor, and preliminary evidence suggests LRP1B-mutated cancers may have improved outcomes with immune checkpoint ... -
Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor.
(Case reports in urology, 2020-01)<h4>Background</h4>Donor-derived malignancy is a rare complication in patients who undergo organ transplant. Approaches to treatment have largely been individualized based on clinical circumstances given the lack ... -
Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.
(Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020-03)<h4>Background</h4>Neoadjuvant cisplatin-based combination chemotherapy for muscle-invasive bladder cancer (MIBC) improves overall and disease-free survival. However, there is much debate over the optimal neoadjuvant regimen. ...
